BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 791317)

  • 1. Resuspension of platelets: enhanced 5-hydroxytryptamine-induced aggregation in chlorpromazine treated patients due to changes in platelet properties.
    Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
    Br J Clin Pharmacol; 1975 Feb; 2(1):37-9. PubMed ID: 791317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine.
    Boullin DJ; Woods HF; Grimes RP; Grahame-Smith DG
    Br J Clin Pharmacol; 1975 Feb; 2(1):29-35. PubMed ID: 791316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin receptor site in human platelets from control and chlorpromazine treated subjects.
    Oppenheim B; Hefez A; Youdim MB
    Prog Biochem Pharmacol; 1980; 16():119-32. PubMed ID: 7443729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased platelet aggregation in patients receiving chlorpromazine: responses to 5-hydroxytryptamine, dopamine and N-dimethyl dopamine.
    Boullin DJ; Grimes RP
    Br J Clin Pharmacol; 1976 Aug; 3(4):649-53. PubMed ID: 22216508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increases in aggregation by and uptake of 5-hydroxytryptamine with platelets from rabbits treated with chlorpromazine.
    Baldacci M; Baldacci M; Bergel TD; Born GV; Hickman M
    Br J Pharmacol; 1980 May; 69(1):113-8. PubMed ID: 7378650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
    Youdim MB; Hefez A; Oppenheim B
    Br J Clin Pharmacol; 1981 Oct; 12(4):535-42. PubMed ID: 7295487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chlorpromazine on serotonin uptake in blood platelets.
    Arora RC; Meltzer HY
    Psychiatry Res; 1983 May; 9(1):23-8. PubMed ID: 6577481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
    Michal F; Motamed M
    Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.
    Boullin DJ; Grahame-Smith DG; Grimes RP; Woods HF
    Br J Pharmacol; 1975 Jan; 53(1):121-5. PubMed ID: 1125484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet function after the administration of chlorpromazine to human subjects.
    Warlow C; Ogston D; Douglas AS
    Haemostasis; 1976; 5(1):21-6. PubMed ID: 1269995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
    Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
    Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative effect of chlorpromazine, imipramine and papaverine on the blood platelet function].
    Bartel' V; Gluza E; Markvardt F
    Farmakol Toksikol; 1976; 39(3):296-301. PubMed ID: 193725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of reserpine and chlorpromazine on 5-hydroxytryptamine uptake of platelets from migrainous and control subjects.
    Hilton BP
    J Neurol Neurosurg Psychiatry; 1974 Jun; 37(6):711-4. PubMed ID: 4844137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of aggregation of rabbit and human platelets induced by adrenaline and 5-hydroxytryptamine by KB-R7943, a Na(+)/Ca(2+) exchange inhibitor.
    Takano S; Kimura J; Ono T
    Br J Pharmacol; 2001 Apr; 132(7):1383-8. PubMed ID: 11264230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of receptors mediating 5-hydroxytryptamine- and catecholamine-induced platelet aggregation, assessed by the actions of alpha- and beta-blockers, butyrophenones, 5-HT antagonists and chlorpromazine.
    Boullin DJ; Glenton PA
    Br J Pharmacol; 1978 Apr; 62(4):537-42. PubMed ID: 26445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of ADP-induced aggregation by 5-HT in rabbit platelets.
    Li BY; Bai Y; Li WH
    Zhongguo Yao Li Xue Bao; 1998 Jan; 19(1):58-62. PubMed ID: 10375761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 5-hydroxytryptamine and epinephrine on newborn platelets.
    Alebouyeh M; Lusher JM; Ameri MR; Evans RK; Robinson A
    Eur J Pediatr; 1978 Jul; 128(3):163-8. PubMed ID: 668724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actions and interactions of ADP, 5- HT, histamine and PAF on equine platelets.
    Bailey SR; Andrews MJ; Elliott J; Cunningham F
    Res Vet Sci; 2000 Apr; 68(2):175-80. PubMed ID: 10756136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S26-8. PubMed ID: 2412051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.